Compare RHP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHP | RYTM |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.4B |
| IPO Year | 1991 | 2017 |
| Metric | RHP | RYTM |
|---|---|---|
| Price | $97.95 | $112.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $108.50 | ★ $125.77 |
| AVG Volume (30 Days) | 467.3K | ★ 887.7K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.77 | N/A |
| Revenue | ★ $2,486,871,000.00 | $174,334,000.00 |
| Revenue This Year | $10.19 | $47.34 |
| Revenue Next Year | $8.07 | $57.18 |
| P/E Ratio | $26.00 | ★ N/A |
| Revenue Growth | 6.48 | ★ 54.92 |
| 52 Week Low | $76.27 | $45.91 |
| 52 Week High | $118.03 | $122.20 |
| Indicator | RHP | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 58.22 |
| Support Level | $91.33 | $109.59 |
| Resistance Level | $95.24 | $122.20 |
| Average True Range (ATR) | 2.05 | 5.23 |
| MACD | 0.38 | 1.08 |
| Stochastic Oscillator | 92.24 | 56.61 |
Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; Gaylord National Resort & Convention Center; and Gaylord Rockies Resort & Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.